Syracuse Orthopedic Specialists Selects Veradigm to Achieve Exceptional Financial Health and Operational Efficiency
Veradigm to provide a comprehensive solution set to optimize revenue cycle and coding processes
CHICAGO, April 02, 2025--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that Syracuse Orthopedic Specialists has selected elements from the Veradigm solution suite, Veradigm Revenue Cycle Services and Coding Services designed to support growth, improve cash flow and reduce costs. Syracuse Orthopedic Specialists, located near Syracuse, NY, provides total orthopedic care to the surrounding regions, and is currently utilizing Veradigm Revenue Analytics, Veradigm Practice Management and Veradigm Payerpath.
Veradigm Revenue Cycle Services provides a robust suite of solutions designed to enhance healthcare revenue cycle management (RCM). This EHR-agnostic healthcare RCM service empowers healthcare providers to lower accounts receivable (AR) days, reduce claim errors, and generate fewer denials. Veradigm Coding Services seamlessly integrates with a practice's electronic health record (EHR) system, identifying deficiencies, optimizing coding and claims workflow. Veradigm works collaboratively with practices to manage complex exceptions, increase first-pass claims, and expedite revenue generation.
"Veradigm has been a trusted partner throughout the years, so it really made sense for us to extend our agreement and adopt its turn-key revenue cycle management solution to complement our existing platform," said Mike Humphrey, Chief Executive Officer of Syracuse Orthopedic Specialists. "When we sought a partner to help streamline our business, we knew we could count on Veradigm's expertise to handle billing, reduce staff burden and increase revenue."
"Today's healthcare provider practices are facing staff and practice operations challenges that can make navigating the end-to-end revenue cycle more difficult than ever," said Tom Langan, Interim Chief Executive Officer of Veradigm. "Our revenue cycle management solution will streamline workflow and free up time and resources for Syracuse Orthopedic Specialists. We are excited to extend our relationship with the Syracuse Orthopedic Specialist team."
About Veradigm®
Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.
© 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402960971/en/
Contacts
Investors:Jenny Gelinas312-506-1237jenny.gelinas@veradigm.com
Media:Amanda Cohen412-919-2417amanda.cohen@veradigm.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
3 hours ago
- CNET
How Boston Dynamics' Atlas Humanoid Robot Sees the World
Back Services & Software All the news and tips you need to get the most out of services, apps and software you use every day.
Yahoo
2 days ago
- Yahoo
Are You Looking for a Top Momentum Pick? Why Cintas (CTAS) is a Great Choice
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at Cintas (CTAS), which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Cintas currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period. You can see the current list of Zacks #1 Rank Stocks here >>> In order to see if CTAS is a promising momentum pick, let's examine some Momentum Style elements to see if this uniform rental company holds up. Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area. For CTAS, shares are up 1.89% over the past week while the Zacks Business - Services industry is flat over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 5.55% compares favorably with the industry's 0.97% performance as well. Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Over the past quarter, shares of Cintas have risen 19.06%, and are up 33.05% in the last year. In comparison, the S&P 500 has only moved 1.99% and 12.34%, respectively. Investors should also take note of CTAS's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now, CTAS is averaging 1,291,825 shares for the last 20 days. The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with CTAS. Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. These revisions helped boost CTAS's consensus estimate, increasing from $4.38 to $4.39 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period. Taking into account all of these elements, it should come as no surprise that CTAS is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Cintas on your short list. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cintas Corporation (CTAS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
3 days ago
- Yahoo
Apple App Store Sales Jump In May, Boosting Outlook For Services Growth
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. JP Morgan analyst Samik Chatterjee had an Overweight rating on Apple Inc (NASDAQ:AAPL) on Tuesday. Apple's App Store revenue for May, tracked by Sensor Tower, increased by 4.9% month-over-month (which compares to an average sequential uptick of 2.3% seen historically going from April to May) and helped support an acceleration of year-over-year revenue trends to up 13.0% Y/Y in May (versus up 11.8% Y/Y in April), Chatterjee stated. While the management did not provide official guidance for Services revenue growth for the calendar second quarter or fiscal third quarter, the analyst noted the latest monthly revenue trends for the App Store to be supportive of Services growth tracking in line with his forecast for low-double-digit year-over-year growth, contrary to investor concerns from the lack of an explicit guide. Don't Miss: Start investing with eToro's CopyTrader — mirror top-performing traders with no management fees, and receive a $10 bonus when you deposit $100 today. Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today. Chatterjee remarked that in May, App Store downloads increased by 2.0% month over month (versus a decline of 4.6 % M/M in April), compared to an average sequential change of 0.1% decline seen historically from April to May. The analyst said that on a year-over-year basis, the App Store downloads increased by 3.1% in May (versus +5.8% in April). On the flip side, some experts cite research pointing toward growth issues for Apple's iPhone. Counterpoint Research has cut growth expectations for global smartphone shipments in 2025 to 1.9% on Wednesday, down from 4.2% previously, citing Trump administration tariff-related uncertainties. The firm also revised shipment growth from China down to near flat and expects Apple and Samsung Electronics shipments to slow as the companies pass the cost burden on consumers. Other research from IDC expects the U.S. smartphone shipment to grow by 1.9% in 2025, down from 3.3% in 2017, due to increased uncertainty and tariff-related price increases. Meanwhile, Deepwater Research's Gene Munster estimated that Apple has about two years to perfect its AI strategy, but it will require increased investments. Read Next: Nancy Pelosi Invested $5 Million In An AI Company Last Year — Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000. Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold. Photo by hanohiki via Shutterstock This article Apple App Store Sales Jump In May, Boosting Outlook For Services Growth originally appeared on
